Atizar vs Genomi

Atizar and Genomi are both agent frameworks tracked by AIDiveForge. Below is a side-by-side comparison of pricing, capabilities, platforms, and ownership — sourced from each tool's live website and verified before publishing.

Atizar

Atizar is an open-source, TypeScript-native framework for building agent workflows where humans stay in the loop before consequential actions execute. The core pattern: agents plan and gather, then pause for a sign-off before anything ships — emails send, records update, data moves. That approval gate is architectural, not bolted on after the fact. The self-hosted option means client deliveries stay off third-party infrastructure. Where it gets tight is documentation depth — the README carries most of the guidance, which means teams building complex branching logic are reading source code before long.

Genomi

The core workflow is four steps: install the agent harness, point it at your raw genome file on disk, build a local SQLite index, then ask questions through whichever AI agent you already run — Claude Code, Cursor, Gemini CLI, Goose, and others are listed as compatible. Pharmacogenomics, carrier status, polygenic risk scores, nutrigenomics, and ancestry PCA projection are all covered through distinct skill modules backed by ClinVar, PharmCAT, PGS Catalog, HPO, GenCC, and 1000 Genomes reference data. The privacy architecture is explicit: raw genome data stays on disk, and only the specific evidence snippets relevant to a query cross the boundary to whatever LLM handles the response. The vendor marks this as experimental and not for clinical use — which means researchers and privacy-conscious individuals exploring personal data are the intended audience, not clinical teams expecting diagnostic-grade output.

Attribute	Atizar	Genomi
Pricing	Free	Free
Free trial	No	No
Open source	Yes	Yes
Has API	Yes	No
Self-hosted option	Yes	Yes
Platforms	Node.js, TypeScript, React (UI)	Linux, macOS, Windows (Python-based)
Released	—	2024
Pros	Human approval gates built into the execution model, so consequential actions — sending emails, updating records — cannot fire without a sign-off, which means you can hand this to a client without writing a separate audit wrapper. TypeScript-native agent code, so the workflow logic lives in the same codebase as the rest of your application — no context-switching to a separate DSL or canvas that generates code you didn't write. Self-hosted deployment option, so client data stays on infrastructure you control and you are not dependent on a third-party cloud runtime going down or changing its pricing. Open-source codebase, so when the docs run out — and they do run out — you can read what the framework actually does rather than waiting on a support ticket. API available, so the agent workflow is addressable from external systems, which means you can trigger automations from existing client tooling without rebuilding their stack around this framework.	Local-first data architecture keeps the raw genome file on disk and only sends queried evidence snippets to the LLM, so teams with strict data policies can explore personal genomic data without uploading a single variant to a third-party server. Skill modules cover pharmacogenomics via PharmCAT and ClinPGx, carrier status via ClinVar and HPO, polygenic risk via PGS Catalog, and ancestry via 1000 Genomes PCA — so a researcher doesn't have to stitch together five separate tools and manually reconcile their outputs. Each answer carries source attribution and stated evidence limits, which means you can trace a finding back to ClinVar or GenCC rather than accepting a response with no provenance — a real gap in generic LLM genomic Q&A. Agent-agnostic MCP and skills-host architecture plugs into whichever AI agent a team already runs, so there is no forced migration to a new interface or locked-in model provider. Apache-2.0 open-source license with self-hosted deployment means developers building agent-based genomic analysis tools can inspect, modify, and extend the skill layer without negotiating commercial terms.
Cons	Documentation is thin beyond the README: teams building anything past the described use cases are reading source code to understand behavior, which adds days to scoping and slows onboarding for developers new to the project. No pre-built connectors or integration library is described in the repo or site — every SaaS connection your agent needs is a custom implementation, which means a five-integration workflow is five separate integration builds before you write a line of agent logic. The framework has no visual builder or canvas, so non-technical stakeholders cannot inspect or modify workflows without developer involvement; teams that need clients to configure their own automations will hit this wall immediately and typically move to a no-code-adjacent platform like n8n or Dify instead. Community size appears small based on available repo signals, which means when you encounter an edge case — and agent workflows generate edge cases reliably — there is precious little prior art to search before it becomes a support or debugging task you own entirely.	Installation requires following a source-code setup guide and configuring an AI agent to connect to the harness — non-technical users hit a wall before they ask a single question, and there is no hosted web interface to fall back on. The project is vendor-labeled experimental, which means skill coverage, reference database freshness, and edge-case handling are not production-guaranteed; teams relying on consistent outputs for any regulated or clinical-adjacent workflow will find the absence of validation documentation disqualifying and will move to a certified clinical genomics platform instead. There is no hosted API, so teams building products that need to serve genomic queries to end users must provision and maintain their own infrastructure — at scale, that maintenance burden is not accounted for in the zero-cost licensing. Evidence snippets sent to an external LLM during a query still cross a data boundary, even if the raw genome file stays local; teams operating under strict genomic data agreements need to verify that snippet-level transmission satisfies their compliance posture before deploying, and the tool provides no compliance documentation to support that review.

Bottom line

Only Atizar exposes a public API. Choose based on which difference matters most for your workflow.

Frequently asked questions

What is the difference between Atizar and Genomi?

Atizar is Free and open source, while Genomi is Free and open source. Compare pricing, free trial, API, platforms, and pros/cons in the table above on AIDiveForge.

Is Atizar better than Genomi?

It depends on your workflow. Use the side-by-side attributes (pricing, open source, API, self-hosted, platforms) to decide. AIDiveForge does not rank a universal winner — we publish verified facts so you can choose.

Atizar vs Genomi: which should I pick?

Pick Atizar if its pricing model, openness, or platform fit matches your constraints; pick Genomi otherwise. Check free-trial availability on each listing if you want to test before committing.

Comparison data is sourced and verified by the AIDiveForge data pipeline. AIDiveForge is editorially independent.